In an increasing number of countries, demonstrating product value in both clinical and economic terms is an important driver of reimbursement listing and optimising the price in different countries. IMS has extensive experience in preparing and submitting high quality reimbursement dossiers, including submissions to the regulatory "gold standard" organizations of Australia and the UK but also many other countries.
Healthcare payers increasingly require health economic evaluations
Reimbursement
Health insurance offsets the cost of treatment and management of illness. Whether an insurer is private or public the principle remains the same: the beneficiary agrees to pay a fixed premium, and in return, the insurance provider agrees to reimburse defined medical costs.
With the current escalation in medical treatment costs and number of treatment options, many insurance providers now insist that a manufacturer demonstrates a product's cost-effectiveness before agreeing to list it for reimbursement.
A compelling need
To satisfy the rising demands of individual reimbursement authorities worldwide, manufacturers must submit clear and evidence-based documentation. This requires a range of multidisciplinary skills that address tasks such as critical review, meta-analysis, health economics evaluation and budget modelling. Many companies involved in product development are not equipped to address these demands.
The IMS HEOR Solution
Since the early 1990's IMS has been a leader in preparing and submitting the documentation required to attain reimbursement listings worldwide:
-
Asia and New Zealand
-
Australia
-
Canada
-
Western Europe
-
Central and Eastern Europe
-
Middle East and South Africa
- US
Our vast global experience and in-depth local knowledge are invaluable in preparing and compiling unbiased, evidence-based documentation for established as well as emerging markets.